Skip to main content
. 2011 Oct 20;16(11):1508–1519. doi: 10.1634/theoncologist.2011-0115

Table 2.

Dose modification schedule for HFSR/HFS during the SOLTI-0701 and NU07B1 trials

graphic file with name onc01111-0916-t02.jpg

In addition to dose modification, symptomatic treatment (e.g., topical therapy) was also recommended for any grade HFSR/HFS.

This is intended as a brief summary of the management guidance for HFSR/HFS from the study protocols of the SOLTI-0701 and NU07B1 trials and is not the complete protocol guidance.

aDose could be titrated to 1,250 mg/m2 as tolerated.

bReduce dose at restart after each occurrence/recurrence is resolved.

cLasting ≥21 days in duration.

Abbreviations: BID, twice daily; CAP, capecitabine; HFS, hand–foot syndrome; HFSR, hand–foot skin reaction; PAC, paclitaxel; PL, placebo; QD, once daily; QOD, once every other day.